initial public offerings (IPOs) trading on American exchanges

Friday, February 28, 2014

Flexion Therapeutics (FLXN) began trading on the NASDAQ on 12 February 2014


Flexion Therapeutics, Inc. (Flexion Therapeutics) is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis, referred to as OA. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. FX007 is a locally administered TrkA receptor antagonist for persistent relief of post-operative pain, including in patients who have received total joint replacement, also referred to as total joint arthroplasty (TJA).


Suite 301, 10 Mall Road
United States

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin--
Operating margin--
EBITD margin--
Return on average assets-84.08%-73.18%
Return on average equity--

No comments:

Post a Comment